A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg od, lumiracoxib 100mg bid and celecoxib 200mg od in patients with primary osteoarthritis of hip, knee, hand or spine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001132-23-IT

Enrollment

3000

Registered

2007-03-13

Start date

2004-07-01

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis MedDRA version: 6.1 Level: PT Classification code 10031164

Interventions

Trade Name: Lumiracoxib Product Name: lumiracoxib Product Code: COX189A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Lumiracoxib Current Sponsor code: CCOX189A2369 Concentration unit:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026